| 2025-12-15 |
详情>>
内部人交易：
West Nadja股份减少2178.00股
|
| 2025-10-28 |
详情>>
股本变动：
变动后总股本8788.50万股
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益11.37美元,归母净利润10.36亿美元,同比去年增长-64.05%
|
| 2025-10-28 |
财报披露：
美东时间 2025-10-28 盘前发布财报
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益7.49美元,归母净利润6.94亿美元,同比去年增长-71.2%
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益4.31美元,归母净利润4.06亿美元,同比去年增长-81.13%
|
| 2025-04-11 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect the 13 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2025.
4.To vote on a shareholder proposal, if properly presented at the meeting.
|
| 2025-02-18 |
详情>>
业绩披露：
2024年年报每股收益33.02美元,归母净利润32.00亿美元,同比去年增长423.73%
|
| 2025-02-18 |
详情>>
业绩披露：
2022年年报每股收益3.84美元,归母净利润4.11亿美元,同比去年增长-55.03%
|
| 2024-10-29 |
详情>>
业绩披露：
2024年三季报(累计)每股收益29.56美元,归母净利润28.82亿美元,同比去年增长685.29%
|
| 2024-07-30 |
详情>>
业绩披露：
2023年中报每股收益2.61美元,归母净利润2.66亿美元,同比去年增长49.44%
|
| 2024-07-30 |
详情>>
业绩披露：
2024年中报每股收益24.49美元,归母净利润24.10亿美元,同比去年增长806.02%
|
| 2024-04-30 |
详情>>
业绩披露：
2024年一季报每股收益21.60美元,归母净利润21.51亿美元,同比去年增长1404.20%
|
| 2024-04-12 |
股东大会：
将于2024-05-22召开股东大会
会议内容 ▼▲
- 1.To elect the 13 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2024.
4.To vote on two shareholder proposals, if properly presented at the meeting.
|
| 2024-02-16 |
详情>>
业绩披露：
2023年年报每股收益6.01美元,归母净利润6.11亿美元,同比去年增长48.66%
|
| 2023-10-30 |
详情>>
业绩披露：
2023年三季报(累计)每股收益3.60美元,归母净利润3.67亿美元,同比去年增长18.77%
|
| 2023-04-14 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect the ten directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To vote, on an advisory basis, on the frequency of future advisory votes to approve the Company’s executive compensation.
4.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2023.
5.To vote on a shareholder proposal requesting a report on patients’ right to access abortion in emergencies, if properly presented at the meeting.
|
| 2022-03-25 |
股东大会：
将于2022-05-06召开股东大会
会议内容 ▼▲
- 1.To elect the eleven directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To approve the First Amendment to the Tenet Healthcare 2019 Stock Incentive Plan.
4.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2022.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-26 |
股东大会：
将于2021-05-06召开股东大会
会议内容 ▼▲
- 1.To elect the eleven directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2021.
4.To transact any other business that properly comes before the meeting or any adjournment or postponement of the meeting.
|
| 2020-04-17 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect the ten directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2020.
4.To vote on a shareholder proposal regarding an independent board chairman, if properly presented at the meeting.
5.To transact any other business that properly comes before the meeting or any adjournment or postponement of the meeting.
|
| 2019-03-22 |
股东大会：
将于2019-05-02召开股东大会
会议内容 ▼▲
- 1.To elect the ten directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal.
2.To vote, on an advisory basis, to approve the Company’s executive compensation.
3.To approve the Tenet Healthcare 2019 Stock Incentive Plan.
4.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2019.
5.To transact any other business that properly comes before the meeting or any adjournment or postponement of the meeting.
|
| 2018-03-30 |
股东大会：
将于2018-05-03召开股东大会
会议内容 ▼▲
- 1.To elect the eight directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal. Your Board of Directors recommends a vote for each director nominee.
2.To vote, on an advisory basis, to approve the Company’s executive compensation. Your Board of Directors recommends a vote for this proposal.
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accountants for the year ending December 31, 2018. Your Board of Directors recommends a vote for this proposal.
4.To vote on a shareholder proposal regarding an independent board chairman, if properly presented at the meeting. Your Board of Directors recommends a vote against this proposal.
5.To transact any other business that properly comes before the meeting or any adjournment or postponement.
|
| 2017-03-24 |
股东大会：
将于2017-05-04召开股东大会
会议内容 ▼▲
- 1.To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal;
2.To vote, on an advisory basis, to approve the company’s executive compensation;
3.To vote, on an advisory basis, on the frequency of future advisory votes to approve the company’s executive compensation;
4.To approve the material terms of the performance goals under the Third Amended Tenet Healthcare Corporation Annual Incentive Plan;
5.To ratify the selection of Deloitte & Touche LLP as independent registered public accountants for the year ending December 31, 2017;
6.To transact any other business that properly comes before the meeting or any adjournment or postponement.
|
| 2016-03-31 |
股东大会：
将于2016-05-12召开股东大会
会议内容 ▼▲
- 1.To elect the 12 directors named in the accompanying Proxy Statement, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected and qualified, whichever is later, or until the director’s earlier resignation or removal;
2.To vote, on an advisory basis, to approve the company’s executive compensation;
3.To approve the Sixth Amended and Restated Tenet Healthcare 2008 Stock Incentive Plan;
4.To approve the Tenet Healthcare Corporation Eleventh Amended and Restated 1995 Employee Stock Purchase Plan;
5.To ratify the selection of Deloitte & Touche LLP as independent registered public accountants for the year ending December 31, 2016;
6.To transact any other business that properly comes before the meeting or any adjournment or postponement.
|
| 2012-06-28 |
复牌提示：
2012-06-28 10:19:11 停牌，复牌日期 2012-06-28 10:24:16
|